April Qing and rain suddenly clear, Nans&•han when the door to turn clear. Sinc¶≠e the establishment and operation of the ×‍new R&D center, Nanjing REGENECORE has f ₩★urther implemented the strategic planning of t♦✘he development and research of antibody≤✔→' drugs and cell therapy. In order ♥λ♣"to better promote the research and development o ←f REGENECORE, in April 2021, the leade✔₩$rs of the group visited Nanjing REG→≤ ENECORE new research and d‍↓evelopment center for work guidance.

Professor Xie Wei, chief sci>≥≈‌entist of REGENECORE, and Wang Yang, general mana↕↔ger of REGENECORE attended the meeting. At≠ Ω the work guidance meeting,π$‍‍ Wang Yang, general manager of Regene™ ✘core, reported the developmentΩ‍≥ of the company's staff an'λ  d team in the first quarter of 2021 and t‌↑he progress of the research and developm↓붙ent work, focusing on the wo♠ ÷rk progress of the company'∏↕§☆;s first antibody drug projec♠←$t RC14/16, and further reported ₩∏the company's research and d←>‍evelopment goals and plans in the second ↑←quarter of 2021.

In the first quarter o"♣★'f 2021, REGENECORE ex®≠©®panded its staff according t≈£>o the overall plan of the compa≈₹ny at the beginning of the year. At t✔λ★☆his work guidance meeting, Chairman Lv Xia"♦ngyang and the leaders of the group optimize∏ d the organizational structure of Regenecore↑₽€' and put forward new requirement☆€≈s for the research and development of Rege ↓← necore. Under the leadership of the ♣≈"group, REGENECORE goes do&§wn every step is solid and p>≠​owerful. Every employee of REGENECORE will str¶↔≠₩ive to make progress in the future work, and str±♥©λive to achieve research and develop¶>ment results as soon as possible to ×ε‍λgenerate income for the group!